China SXT Pharmaceuticals 주식 (NASDAQ: SXTC)

에 대한 최신 뉴스 China SXT Pharmaceuticals (NASDAQ:SXTC) 주식

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals Inc

As Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) retreats to three-month lows, the 9% correction in total crypto market capitalization has analysts speculating about what is <a href="https://in.benzinga.com/news/global/25/02/43926015/trump-confirms-tariffs-on-canada-mexico-will-take-effect-as-planned">driving this downturn</a>.
What Happened: In a detailed thread on <a href="https://x.com/KobeissiLetter/status/1894218914923417964">X</a> on Tuesday, macro commentary account Kobeissi Letter described the correction as a liquidity cascade triggered by multiple compounding factors. 
The aggressive sell-off in Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), combined with a broader risk-off move in equities, likely sparked a wave of liquidations across crypto.
Solana is down 17.2% in the past seven days and 44.9% over the past month. Leading meme coins like Trump (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>), Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>) and Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) are down 21%, 17% and 14%, respectively.
According to Kobeissi Letter, the meme coin market losing liquidity is a notable signal, signaling broader risk appetite is fading. CoinGecko data shows the total meme coin market cap down 16.5% over the past 24 hours.
The crypto market has shed close to <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43937601/bitcoin-down-7-ethereum-xrp-dogecoin-shiba-inu-plunge-over-10-as-148-billion-liquidation-t">$1.5 billion in liquidations</a> as part of the market correction.
Interestingly, this market correction comes on the heels of <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43923960/citadel-securities-moves-into-crypto-market-making-following-trumps-crypto-friendly-regula">Citadel Securities&#8217; announcement</a> of plans to become a liquidity provider for Bitcoin and crypto. The market seems to have interpreted this as a &#8220;sell the news&#8221; event.
The recent <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43905078/bybit-nears-recovery-after-crypto-heist-freezes-42-89-million-in-stolen-funds-secures-1-23-billion-in-eth-through-whales-and-loans">Bybit hack on Feb. 21</a> has also dampened market sentiment. Arkham Intelligence has labeled this incident as the &#8220;largest financial heist in history,&#8221; surpassing even the Central Bank of Iraq theft in 2003.
Price Action: Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is down 7% over the past 24 hours, trading around $88,800 at the time of writing. Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) are down 9%, trading at $2,415 and $2,22, respectively.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43934933/bitcoin-plunges-below-88000-what-is-going-on">Bitcoin Plunges Below $88,000: What Is Going On?</a>
What's Next: Technical factors and a general pullback in risk appetite across financial markets have contributed to the crypto market&#8217;s liquidity squeeze. 
The Kobeissi Letter notes, &#8220;We saw historic levels of risk appetite in 2024 and heading into 2025. A pullback in risk appetite means less liquidity for crypto markets.&#8221;
While the current situation may seem alarming, it&#8217;s worth noting that Bitcoin has experienced numerous 10% pullbacks during its bull run. 
The Kobeissi Letter suggests that &#8220;Technical pullbacks are healthy&#8221; and doesn&#8217;t necessarily indicate a prolonged bear market.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43918143/bitcoin-stuck-in-90-day-consolidation-range-this-juncture-is-critical-bitfinex-analysts-say">Bitcoin Stuck In 90-Day Consolidation Range: This Juncture Is Critical, Bitfinex Analysts Say</a></li>
</ul>
Image: Shutterstock

$BONK

$BTC

$ETH

$SOL

$TRUMP

$WIF

$XRP

Bitcoin, Ethereum, XRP Shed Billions In 9% Correction: 3 Factors Driving The Downturn

The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) has outperformed the market over the past 5 years by 2.38% on an annualized basis producing an average annual return of 16.46%. Currently, The Hartford Insurance Gr has a market capitalization of $32.48 billion. 
Buying $100 In HIG: If an investor had bought $100 of HIG stock 5 years ago, it would be worth $227.87 today based on a price of $113.82 for HIG at the time of writing.
<h3>The Hartford Insurance Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740492910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In The Hartford Insurance Gr 5 Years Ago Would Be Worth This Much Today

<ul>
<li>NVDA</li>
<li>SMCI</li>
<li>PLTR</li>
<li>TSLA</li>
<li>LUNR</li>
<li>CORN</li>
<li>MSTR</li>
<li>HIMS</li>
<li>$BTC</li>
<li>GLD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

CORN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LUNR

MSTR

NVDA

PLTR

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of February 25, 2025 (Via Swaggy Stocks)

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) with a Overweight rating.

Initiation

Analyst Ratings

MTSR

Cantor Fitzgerald Initiates Coverage On Metsera with Overweight Rating

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and maintains $32 price target.

Price Target

CMPX

D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $32 Price Target

Baird analyst William Power maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Neutral and lowers the price target from $38 to $32.

Baird Maintains Neutral on RingCentral, Lowers Price Target to $32

On Monday, Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the <a href="https://www.benzinga.com/pressreleases/25/02/g43923628/latest-db-oto-results-demonstrate-clinically-meaningful-hearing-improvements-in-nearly-all-childre" target="_blank" rel="noreferrer noopener">otoferlin (OTOF) gene</a>.
Regeneron snapped up DB-OTO through its&nbsp;$109 million acquisition&nbsp;of Decibel Therapeutics <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33664344/decibel-therapeutics-stock-soars-on-acquisition-deal-the-details" rel="noreferrer noopener">in August 2023</a>.
Congenital deafness (hearing loss present at birth) affects approximately 1.7 out of every 1,000 children born in the U.S. Approximately half of these cases have genetic causes.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43470883/regenerons-q4-earnings-surpass-estimates-launches-quarterly-dividend-and-additional-stock-buyback-program" rel="noreferrer noopener">Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program</a>
However, otoferlin-related hearing loss is ultra-rare. It is caused by variants in the OTOF gene, which lead to a lack of a functional otoferlin protein critical for communication between the inner ear&#8217;s sensory cells and the auditory nerve.
These include 72-week results showing speech and development progress in the first child dosed at 10 months of age and initial results in 11 children (aged 10 months to 16 years old) – three of whom received DB-OTO bilaterally (in both ears).
Among the 11 participants with at least one post-treatment assessment, 10 demonstrated a notable response, with improved hearing at various decibel hearing levels. Additionally, among five participants with 24-week assessments, three experienced improvements in average hearing thresholds to &#8220;nearly normal&#8221; or normal hearing levels.
One participant did not experience a change from their baseline hearing at 24 weeks post-dosing.
Across all 12 participants, the surgical procedure and DB-OTO were well tolerated and no adverse or serious adverse events were considered related to DB-OTO.
Five of the 12 participants experienced transient post-surgical vestibular adverse events (e.g., nystagmus, nausea, dizziness, vomiting), which resolved within 6 days of dosing.
Price Action: REGN stock closed at $713.25 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/02/43910591/fresh-del-monte-stock-falls-as-q4-sales-earnings-miss-expectations" target="_blank" rel="noreferrer noopener">Fresh Del Monte Stock Falls As Q4 Sales &amp; Earnings Miss Expectations</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

REGN

Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss

Keybanc analyst Sangita Jain maintains KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) with a Overweight and lowers the price target from $70 to $67.

Keybanc Maintains Overweight on KBR, Lowers Price Target to $67

Contracts

AREB

Champion Safe  and Wholly-Owned Subsidiary Of American Rebel Holding Enters A Strategic Partnership With Netwize, To Modernize And Optimize Its Technology Infrastructure

WIIM

SLXN

Silexion therapeutics shares are trading higher after the company announced the completion of its initial study in orthotopic pancreatic cancer models evaluating systemic administration of SIL-204.

TZOO

Travelzoo shares are trading lower following worse-than-expected Q4 reported financial results.

Keybanc analyst Tim Rezvan initiates coverage on Infinity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) with a Overweight rating and announces Price Target of $26.

Morgan Stanley Market Vectors Rupee/USD ETN

Keybanc Initiates Coverage On Infinity with Overweight Rating, Announces Price Target of $26

ZONE

CleanCore Solutions shares are trading higher after the company announced it will acquire Sanzonate Europe.

Susquehanna analyst Christopher Stathoulopoulos maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Neutral and raises the price target from $247 to $250.

Susquehanna Maintains Neutral on Hilton Worldwide Holdings, Raises Price Target to $250

CJET

Chijet Motor: Stock Purchase Agreement With Too Express Group & Holders of Too Express's Outstanding Capital Shares To Acquire 80% Of Equity Interests

SOUN

SoundHound AI Announces AI Platform For Restaurants

Tempus AI Inc Files For Offering Of Up To 4.84M Shares Of Class A Common Stock By The Selling Stockholder

TARS

Tarsus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

Keybanc analyst Tim Rezvan downgrades Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) from Overweight to Sector Weight.

Downgrades

CIVI

Keybanc Downgrades Civitas Resources to Sector Weight

Susquehanna analyst Christopher Stathoulopoulos maintains Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Neutral and raises the price target from $80 to $110.

Comments

China SXT Pharmaceuticals

뉴스

에 대한 최신 뉴스 China SXT Pharmaceuticals (NASDAQ:SXTC) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌